Efficacy of intralesional vitamin D3 in cutaneous warts
Journal of Pakistan Association of Dermatologists · 12.10.2023 · 33 (4) · 1508-1513
DOI: 10.66344/jpad.v33i4.2268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pakistan Association of Dermatologists, online erschienen am 12.10.2023. Verfasst von Maria Naseer und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The objective of this study was to determine the efficacy of intralesional vitamin D3 in cutaneous warts.
Methods
The study comprised 226 patients with palmoplantar warts of various sizes and duration. After injecting lignocaine 0.2 ml (20 mg/ml), about 0.5 mL of vitamin D3 solution (200,000 IU, 15 mg/mL) was administered to the base of the warts. At 2-week intervals, up to 5 warts were injected in each session until they disappeared, which could take up to 4 treatments. Following the final injection, patients were monitored for 6 months to look for any recurrence.
Results
The study included 226 patients. The average number of injections needed to obtain a complete resolution was 2.93±0.60. Complete response was observed in 185 (81.9%) patients.
Conclusion
Cutaneous warts can be treated effectively, affordably, and safely with intralesional vitamin D3.
Zitieren
APA
Naseer, M., Ghafoor, R., & Asad, N. (2023). Efficacy of intralesional vitamin D3 in cutaneous warts. Journal of Pakistan Association of Dermatologists, 33(4), 1508-1513. https://doi.org/10.66344/jpad.v33i4.2268
Vancouver
Naseer M, Ghafoor R, Asad N. Efficacy of intralesional vitamin D3 in cutaneous warts. Journal of Pakistan Association of Dermatologists. 2023;33(4):1508-1513. doi:10.66344/jpad.v33i4.2268
BibTeX
@article{Naseer2023,
author = {Naseer, Maria and Ghafoor, Rabia and Asad, Nazia},
title = {Efficacy of intralesional vitamin D3 in cutaneous warts},
journal = {Journal of Pakistan Association of Dermatologists},
year = {2023},
volume = {33},
number = {4},
pages = {1508--1513},
doi = {10.66344/jpad.v33i4.2268}
}
EUVIMED